Hepatology Research

Article	Citations
MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach	122
Evidence‐based clinical practice guidelines for liver cirrhosis 2020	107
Evidence‐based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020	77
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)	74
MAFLD: Renovation of clinical practice and disease awareness of fatty liver	62
Report of the 22nd nationwide follow‐up Survey of Primary Liver Cancer in Japan (2012–2013)	48
Report of the 21st Nationwide Follow‐up Survey of Primary Liver Cancer in Japan (2010–2011)	42
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice	41
Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan	41
Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study	40
Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease	36
Hepatocellular carcinoma after Fontan surgery: A systematic review	33
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy	33
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma	32
Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study	32
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis	31
Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis	31
Exosome circCMTM3 promotes angiogenesis and tumorigenesis of hepatocellular carcinoma through miR‐3619‐5p/SOX9	26
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis	26
Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen	26
Association of coagulopathy with liver dysfunction in patients with COVID‐19	26
Pathological characteristics of liver sinusoidal thrombosis in COVID‐19 patients: A series of 43 cases	24
Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma	24
Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma	23
Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular‐targeted agent sequential therapy: A propensity score‐matche	23

Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: A single‐arm, pilot study	23
Serum matrix metalloproteinase‐7 in biliary atresia: A Japanese multicenter study	23
Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multic	23
Calf and arm circumference as simple markers for screening sarcopenia in patients with chronic liver disease	22
Zinc deficiency predicts overt hepatic encephalopathy and mortality in liver cirrhosis patients with minimal hepatic encephalopathy	22
Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis	22
Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality in patients with chronic liver disease	21
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis	21
Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria	20
Easy albumin–bilirubin score as a new prognostic predictor in hepatocellular carcinoma	19
Myostatin as a fibroblast‐activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma	19
aMAP score prediction of hepatocellular carcinoma occurrence and incidence‐free rate after a sustained virologic response in chronic hepatitis C	17
Hepatocellular carcinoma and other complications of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A structured review of published works	17
Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression	17
Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection	17
Dysregulation of sphingolipid metabolic enzymes leads to high levels of sphingosine‐1‐phosphate and ceramide in human hepatocellular carcinoma	17
Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era	16
Prognosis of intrahepatic cholangiocarcinoma stratified by albumin–bilirubin grade	16
Characterization of hepatitis B virus DNA integration patterns in intrahepatic cholangiocarcinoma	16
Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study	16
The beneficial impact of metabolic dysfunction‐associated fatty liver disease on lenvatinib treatment in patients with non‐viral hepatocellular carcinoma	15
Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study	15
Novel strategies for the early diagnosis of hepatitis B virus reactivation	15
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis	14
Management of portal hypertension based on portal hemodynamics	14
Association between the albumin–bilirubin (ALBI) score and severity of portopulmonary hypertension (PoPH): A data‐mining analysis	14
Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta‐analysis of propensity score studies	14
Meta‐analysis of the effect of sodium–glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non‐alcoholic fatty liver disease	14
Diagnostic criteria for acute‐on‐chronic liver failure and related disease conditions in Japan	14
Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of Hepatology	13
Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoemboliz	13
Clinical practice guidelines for autoimmune hepatitis	12
A novel rapid immunoassay of serum type IV collagen 7S for the diagnosis of fibrosis stage of nonalcoholic fatty liver diseases	12
Metabolic dysfunction‐associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle‐aged and older US population	12
Proposal of Stroop test cut‐off values as screening for neuropsychological impairments in cirrhosis: A Japanese multicenter study	12
Assessing liver stiffness with conventional cut‐off values overestimates liver fibrosis staging in patients who received the Fontan procedure	12
Treatment outcomes of stereotactic body radiation therapy using a real‐time tumor‐tracking radiotherapy system for hepatocellular carcinomas	12
Effects of a low‐intensity resistance exercise program on serum miR‐630, miR‐5703, and Fractalkine/CX3CL1 expressions in subjects with No exercise habits: A preliminary study	12
Non‐invasive fibrosis markers are associated with mortality risk in both general populations and non‐alcoholic fatty liver disease patients	12
High fatty liver index is an independent predictor of ischemic heart disease during a 10‐year period in a Japanese population	11
Randomized controlled study to examine the efficacy of hepatic arterial infusion chemotherapy with cisplatin before radiofrequency ablation for hepatocellular carcinoma	11
Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease	11
Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population	11
Effects of pemafibrate on primary biliary cholangitis with dyslipidemia	11
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study	11
Development and multicenter validation of FIB‐6: A novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hep	11
Identification of microRNA‐96‐5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma	11
The efficacy of rituximab treatment for antibody‐mediated rejection in liver transplantation: A retrospective Japanese nationwide study	11
Chemical conversion of aged hepatocytes into bipotent liver progenitor cells	10
Single nucleus transcriptomics data integration recapitulates the major cell types in human liver	10

Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core‐related antigen assay	10
Clinical course of hepatitis C virus‐positive patients with decompensated liver cirrhosis in the era of direct‐acting antiviral treatment	10
Novel artificial intelligent/neural network system for staging of nonalcoholic steatohepatitis	10
Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis	10
2‐Step PLT16‐AST44 method: Simplified liver fibrosis detection system in patients with non‐alcoholic fatty liver disease	10
Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)	10
Prognosis of patients with liver cirrhosis: A multi‐center retrospective observational study	9
Case of hepatitis B virus reactivation after ibrutinib therapy in which the patient remained negative for hepatitis B surface antigens throughout the clinical course	9
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: A large‐scale multicenter retrospective study	9
Angiopoietin‐like protein 4 deficiency augments liver fibrosis in liver diseases such as nonalcoholic steatohepatitis in mice through enhanced free cholesterol accumulation in hepatic stellate cells	9
Concordance between metabolic dysfunction‐associated steatotic liver disease and nonalcoholic fatty liver disease	9
Pancreas stiffness in liver cirrhosis is an indicator of insulin secretion caused by portal hypertension and pancreatic congestion	9
Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute‐on‐chronic liver failure development and prognosis in patients with liver cirrhosis	9
Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab	9
The ursodeoxycholic acid response score predicts pathological features in primary biliary cholangitis	9
Hepatic stellate cell as a Mac‐2‐binding protein‐producing cell in patients with liver fibrosis	9
Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection	9
Screening for portopulmonary hypertension using computed tomography‐based measurements of the main pulmonary artery and ascending aorta diameters in patients with portal hypertension	9
LncRNA FGD5‐AS1 enhances the proliferation and stemness of hepatocellular carcinoma cells through targeting miR‐223 and regulating the expression of ECT2 and FAT1	9
Proposal for new sleep disorder criteria in patients with chronic liver disease: Influence of liver‐related complications	9
Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow‐up results of phase IIa clinical study	8
Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients	8
Metabolic dysfunction‐associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients	8
Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis	8
Prognostic significance for recurrence of fibroblast growth factor receptor 2 in intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection	8
Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct‐acting antiviral therapy and achieved sustained	8
Real‐world hospital mortality of liver cirrhosis inpatients in Japan: a large‐scale cohort study using a medical claims database	8
Serum levels of immunoglobulin M‐free inhibitors of macrophage/CD5L as a predictive and early diagnostic marker for nonalcoholic steatohepatitis‐associated hepatocellular carcinoma	8
Multicenter study on the consciousness‐regaining effect of a newly developed artificial liver support system in acute liver failure: An on‐line continuous hemodiafiltration system	8
Impact of body fat accumulation on metabolic dysfunction‐associated fatty liver disease and nonalcoholic fatty liver disease in Japanese male young adults	8
Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma	8
Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib	8
Does immune checkpoint inhibitor exhibit limited efficacy against non‐viral hepatocellular carcinoma?: A review of clinical trials	8
Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample	7
Spleen stiffness in patients with chronic liver disease evaluated by 2‐D shear wave elastography with ultrasound multiparametric imaging	7
Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long‐term effects from a prospective study	7
Donor‐dominant one‐way matching of human leukocyte antigen‐A/B/DR alleles predicts graft‐versus‐host disease following living donor liver transplantation	7
Hepatocellular adenoma, approximately half and predominantly inflammatory subtype, in 38 Japanese patients with several differences in age, gender, and clinical background factors from Western populat	7
Accuracy of carbohydrate‐deficient transferrin as a biomarker of chronic alcohol abuse during treatment for alcoholism	7
Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma	7
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real‐world data	7
Comparison of modified CEUS LI‐RADS with sonazoid and CT/MRI LI‐RADS for diagnosis of hepatocellular carcinoma	7
Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis‐related fibrosis: Multicenter study	7
Changes in disease characteristics of primary biliary cholangitis: An observational retrospective study from 1982 to 2016	7
Impact of non‐obese metabolic dysfunction‐associated fatty liver disease on risk factors for the recurrence of esophageal squamous cell carcinoma treated with endoscopic submucosal dissection: A multi	6
Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug‐eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma	6
The imbalance between NKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virus‐related hepatocellular carcinoma	6
Non‐malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors	6
Serum angiopoietin‐2 levels predict regression of Mac‐2 binding protein glycosylation isomer‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents	6
Immunoglobulin G4 (IgG4)‐related autoimmune hepatitis and IgG4‐hepatopathy: A histopathological and clinical perspective	6
Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease	6
Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body	6
The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis	6
Synthesized HMGB1 peptide prevents the progression of inflammation, steatosis, fibrosis, and tumor occurrence in a non‐alcoholic steatohepatitis mouse model	6
Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir	6
Effects of sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB‐4 index in metabolic‐associated fatty liver disease	6
Time‐resolved 3D cine phase‐contrast magnetic resonance imaging (4D‐flow MRI) can quantitatively assess portosystemic shunt severity and confirm normalization of portal flow after embolization of larg	6
The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A mu	6
Nucleoside/nucleotide analog consolidation therapy in hepatitis B e‐antigen positive chronic hepatitis B patients: Three years should be preferred	6
Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease	6
The hemoglobin, albumin, lymphocyte, and platelet score is a prognostic factor for Child–Pugh A patients undergoing curative hepatic resection for single and small hepatocellular carcinoma	6
Validation of fatty liver index as a predictor of hepatic steatosis in Asian populations: Impact of alcohol consumption and sex	6
Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: Report of a Japanese nationwide survey	6
Circular ribonucleic acid nei‐like deoxyribonucleic acid glycosylase 3 governs the microribonucleic acid ‐3150b‐3p/laminin subunit gamma 1 network to partially promote the development of hepatocellula	6
Impact of antiviral therapy for disease progression and non‐invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis	6
Postoperative direct‐acting antiviral treatment after liver resection in patients with hepatitis C virus‐related hepatocellular carcinoma	6
Hypofractionated radiotherapy for hepatocellular carcinomas adjacent to the gastrointestinal tract	6
Overestimated renal function in patients with liver cirrhosis predicts poor prognosis	6
Mac‐2 binding protein glycan isomer as noninvasive tool to assess liver fibrosis in children with chronic liver disease	5
Atherosclerotic cardiovascular disease in non‐metabolic nonalcoholic fatty liver disease	5
Phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trial	5
Reevaluation of Makuuchi’s criteria for resecting hepatocellular carcinoma: A Japanese nationwide survey	5
Determinants of the effectiveness of bezafibrate combined with ursodeoxycholic acid in patients with primary biliary cholangitis	5
Novel biomarkers of acute kidney injury in chronic liver disease: Where do we stand after a decade of research?	5
Liver fibrosis improvement assessed by magnetic resonance elastography and Mac‐2‐binding protein glycosylation isomer in patients with hepatitis C virus infection receiving direct‐acting antivirals	5
Mitochondrial fission in hepatocytes as a potential therapeutic target for nonalcoholic steatohepatitis	5
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients	5
Multicenter, retrospective, cohort study shows platelet counts predict hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease	5
Predictive model containing gene signature and shear wave elastography to predict patient outcomes after Kasai surgery in biliary atresia	5
Prevalence of anti‐Hepatitis E antibodies and impact on disease severity in non‐alcoholic fatty liver disease	5

Significance of zinc deficiency in patients with hepatocellular carcinoma undergoing hepatic resection	5
Indications and waiting list priority for deceased donor liver transplantation in HIV/HCV co‐infected hemophilic patients in Japan through contaminated blood product	5
Analysis of drug‐induced liver‐related adverse event trend reporting between 1997 and 2019	5
Sofosbuvir–velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan	5
Carbon ion radiotherapy for patients with hepatocellular carcinoma in the caudate lobe	5
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with he	5
Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis	5
The utility of biomarkers in prognosis assessment of patients with acute liver failure	5
Automated image analysis of keratin 7 staining can predict disease outcome in primary sclerosing cholangitis	5
Clinical outcomes of antithrombin III‐based therapy for patients with portal vein thrombosis: A retrospective, multicenter study	5
Absence of large portal collateral vessels is associated with spontaneous improvement of cirrhotic portal vein thrombosis	5
Regulatory function of interferon‐inducible 44‐like for hepatitis B virus covalently closed circular DNA in primary human hepatocytes	5
Severity of liver fibrosis using shear wave elastography is influenced by hepatic necroinflammation in chronic hepatitis patients, but not in cirrhotic patients	5
Agile 3+ and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver‐related events in nonalcoholic fatty liver disease	5
Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α‐fetoprotein: Outcomes by treatment‐emergent ascites	5
Predictors associated with a better response to the Japanese aluminum‐free hepatitis A vaccine, Aimmugen®, for people living with HIV	5
Efficacy of rifaximin, a poorly absorbed rifamycin antimicrobial agent, for hepatic encephalopathy in Japanese patients	5
The promise of radiotherapy for hepatocellular carcinoma	5
Deep sequencing analysis of serum hepatitis B virus‐RNA during nucleot(s)ide analogue therapy	5
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis B	5
Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B	5
Factors associated with liver injury and prognosis in advanced cancer patients treated with immune checkpoint inhibitors	5
Preoperative serum brain‐derived neurotrophic factor as a predictive biomarker for sepsis after living‐donor liver transplantation	5
Metabolomic profiles of breath odor compounds for prognostic prediction in patients with acute‐on‐chronic liver failure: A pilot study	5